COLORADO SPRINGS, Colo., June 21 /PRNewswire-FirstCall/ -- Spectranetics Corporation today announced that it will present at the Jefferies Life Sciences Conference to be held June 27-28 at the Mandarin Oriental Hotel in New York City.
John G. Schulte, Spectranetics’ president and chief executive officer, is scheduled to speak on Tuesday, June 27 at 2:30 p.m. Eastern time (11:30 a.m. Pacific time) and will discuss the Company’s strategic initiatives, product pipeline and market opportunities.
Interested parties can access a live audio webcast at www.spectranetics.com. An archived presentation will be available on the Web site for 14 days.
About Spectranetics
Spectranetics is a medical device company that develops, manufactures and markets single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser system. Its CVX-300(R) excimer laser is the only system approved by the FDA for multiple cardiovascular procedures, including coronary atherectomy, and the removal of problematic pacemaker and defibrillator leads. Nearly all of the company’s FDA-approved and investigational applications have received Communautes Europeennes (CE) mark registration for marketing within Europe. In April 2004 Spectranetics obtained 510(k) clearance from the FDA for the laser-based treatment of patients suffering from total occlusions (blockages) in their leg arteries that are not crossable with a guide wire.
COMPANY CONTACT: INVESTOR & MEDIA CONTACTS: Spectranetics Corporation Lippert/Heilshorn & Associates, Inc. Guy Childs, Chief Financial Officer Bruce Voss or Don Markley (719) 633-8333 (310) 691-7100 www.spectranetics.comwww.lhai.com
Spectranetics Corporation
CONTACT: Guy Childs, Chief Financial Officer of Spectranetics Corporation,+1-719-633-8333; or Investors, Bruce Voss, or Don Markley, both ofLippert/Heilshorn & Associates, Inc., +1-310-691-7100, for SpectraneticsCorporation
